AstraZeneca wins shareholder approval for New York listing
Move by FTSE’s biggest company gains support of 99% of shareholders who voted in blow to London market
Related reading
AstraZeneca bounces back from scandal in China
Pharma group has installed new leadership in the country and pledged $2.5bn for a Beijing R&D centre
AstraZeneca revives Cambridge investment after UK agrees to pay more for drugs
Resumption of £300mn in UK projects is a result of trade deal with US that aims to increase medicines spending
Wise shareholders back plan to move listing from the UK to the US
Fintech sees off investor rebellion led by co-founder, who opposed extension of dual class share structure
What Sweden can teach the world about stock market success
AstraZeneca’s humbling blow to London highlights need for change in UK and elsewhere in Europe
IG Group considers New York listing in latest blow to London’s stock exchange
Online trading group said in a review it would also consider acquisitions
Wise’s wake-up call for London
Decision by the fintech to move primary listing to New York is latest blow to LSE